Funding profile · AI drug discovery software
Angstrom AI
No SEC Form D has been filed under Angstrom AI’s name. What exists instead is a set of disagreeing third-party reports of a seed round, a UK holding company with a shrinking board, and one confirmed pharma collaboration that surfaced through a published paper rather than a funding announcement.
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Summer 2024 | Y Combinator, Summer 2024 batch | Not disclosed | Y Combinator | YC data |
| Jul 2024 | Seed, as reported | $500,000 | Not named in the aggregator record | Data aggregator |
| Sep 2024 | Seed, as reported | Not disclosed | Pioneer Fund (lead, per Preqin); JME Ventures also listed as a current investor | Data aggregator |
| By 2024 | Total funding, as reported | $0 | None; GetLatka lists no funding raised at all | Data aggregator |
| 2024 to 2026 | Pharma pilot, not a financing round | $150,000 pilot fee, company-reported | Unnamed pharma company | Company-stated |
Three data platforms describe three different capital pictures for the same company in the same year. None of them agree on an amount, and none is backed by a Form D.
What the filings show
A search of SEC EDGAR for companies named Angstrom that have filed a Form D turns up two results, Angstrom Bio, Inc. of Texas and Angstrom Technologies Inc. of Kentucky. Neither is Angstrom AI. No Form D, no pooled investment vehicle, and no amended filing was found under Angstrom AI, Ångström AI, or a name close enough to be an obvious match. If Angstrom AI has raised money under Regulation D, no notice of it has reached EDGAR under a name this research could find. It is also possible any raise to date has used an exemption, such as Section 4(a)(2), that does not require a Form D at all.
What does exist is a UK company record. Angstrom Ai Ltd, company number 15640060, was incorporated on April 12, 2024 with a registered office on Great Portland Street in London. Its statement of capital at incorporation was GBP 1. Gabor Csanyi was appointed a director on June 17, 2024. Laurence Midgley’s directorship ended on May 6, 2025, and Javier Antoran’s ended on June 19, 2026. Its most recent confirmation statement, dated April 11, 2026, reported no updates, and its last full accounts were made up to December 31, 2025. Companies House filings carry no share allotment or funding round data beyond the GBP 1 starting capital, which is normal for a UK entity that raises money through a separate US vehicle.
Reading the record
- Three aggregators, three different stories.Preqin names Pioneer Fund as a September 2024 seed investor with JME Ventures also current, Tracxn reports a $500,000 seed round closed in July 2024 without naming an investor, and GetLatka reports zero funding raised. A two month gap between the two seed dates and a full disagreement on amount is a sign these are independent estimates, not restatements of one filing.
- No Form D means no confirmed number.Every dollar figure on this page below the pilot line comes from a third party database, not a regulatory filing. Companies that raise through SAFEs from Y Combinator or through a 4(a)(2) exemption can legitimately have no Form D at all, so the absence is not itself evidence of no funding, only evidence that this research found no confirmed amount.
- The UK entity is a thin shell so far.Angstrom Ai Ltd was capitalized with GBP 1 at incorporation and its filings show director changes but no allotment of new shares. If a seed round happened, the money and the paperwork for it appear to sit somewhere this filing history does not show, most likely a US entity.
- Two of four founding directors have left the UK board.Laurence Midgley left in May 2025 and Javier Antoran left in June 2026, the more recent departure only about three months before this page was written. Gabor Csanyi and Jose Miguel Hernandez-Lobato remain. The filings give no reason for either exit.
- The clearest paper trail is scientific, not financial.Two Journal of the American Chemical Society papers and one 2026 arXiv preprint list an Angstrom AI, San Francisco affiliation for Gabor Csanyi and researcher J Harry Moore. The arXiv preprint also carries five named AstraZeneca co-authors, which is a harder confirmation of a pharma relationship than any funding claim on this page.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Accelerator | Y Combinator, Summer 2024 batch, primary partner Ankit Gupta. Also listed as an Orange Collective portfolio company. | Accelerator record |
| Named pharma collaboration | AstraZeneca’s crystal structure prediction team co-authored a 2026 arXiv preprint with the founders and described the work in a company LinkedIn post. | Public record |
| Unnamed pharma pilot | Company reports a $150,000 pilot with a pharma company, applying its models to solubility estimation. Partner not named. | Company-stated |
| Revenue | GetLatka estimates $900,000 in 2024 revenue. The same profile lists $0 in reported funding, so this figure should be read as a modeled estimate, not a disclosed number. | Data aggregator |
| Team size | Y Combinator lists 5. Tracxn counts 4 as of June 2026. GetLatka estimates 6. | Differs across sources |
What to watch
- Whether a Form D appears under Angstrom AI, Inc. or a similarly named US entity, which would settle the seed amount question.
- Whether Angstrom Ai Ltd allots new shares or is instead wound down as the US side of the business grows.
- Whether AstraZeneca or another pharma partner confirms a commercial deal in its own materials, beyond joint authorship of a paper.
- Whether Javier Antoran’s June 2026 departure from the UK board reflects a change in his role at the company overall.
The Angstrom AI story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordEDGAR company search for companies named Angstrom, Form D filings
- Public recordCompanies House overview, ANGSTROM AI LTD, company number 15640060
- Public recordCompanies House filing history, ANGSTROM AI LTD
- Public recordDFT Accuracy on Crystal Structure Prediction with Machine Learning Interatomic Potentials, arXiv 2605.28905
- Public recordComputing Solvation Free Energies of Small Molecules with Experimental Accuracy
- Data aggregatorAngstrom AI, Inc. asset profile
- Data aggregatorAngstrom AI company and funding profile
- Data aggregatorAngstrom AI revenue and team estimate
- CompanyAngstrom AI company profile and founder bios
- CompanyLaunch YC: Angstrom AI, Gen AI molecular simulations
- CompanyAngstrom AI company page, AstraZeneca CSP-MACE-A post
Compiled from SEC, UK Companies House and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Angstrom AI. This page is not an offer to sell or a recommendation to buy any security.